Publications

Search our bibliography using the filters on the right-hand side.

Displaying 351 through 400 of 467 publications.

Dhamrait SS, Payne JR, Li P, Jones A, Toor IS, Cooper JA, Hawe E, Palmen JM, Wootton PT, Miller GT, Humphries SE, Montgomery HE. Variation in bradykinin receptor genes increases the cardiovascular risk associated with hypertension. Eur Heart J. 2003;24(18):1672-80.

Juhan-Vague I, Morange PE, Frere C, Aillaud MF, Alessi MC, Hawe E, Boquist S, Tornvall P, Yudkin JS, Tremoli E, Margaglione M, Di Minno G, Hamsten A, Humphries SE, HIFMECH Study Group. HIFMECH Study Group. The plasminogen activator inhibitor-1 -675 4G/5G genotype influences the risk of myocardial infarction associated with elevated plasma proinsulin and insulin concentrations in men from Europe: the HIFMECH study. J Thromb Haemost. 2003;1(11):2322-9.

Carew JA, Basso F, Miller GJ, Hawe E, Jackson AA, Humphries SE, Bauer KA. Humphries SE, et al. A functional haplotype in the 5' flanking region of the factor VII gene is associated with an increased risk of coronary heart disease. J Thromb Haemost. 2003;1(10):2179-85.

Abuzeid AM, Hawe E, Humphries SE, Talmud PJ, HIFMECH Study Group. HIFMECH Study Group. Association between the Ala379Val variant of the lipoprotein associated phospholipase A2 and risk of myocardial infarction in the north and south of Europe. Atherosclerosis. 2003;168(2):283-8.

Wong WM, Hawe E, Li LK, Miller GJ, Nicaud V, Pennacchio LA, Humphries SE, Talmud PJ. Apolipoprotein AIV gene variant S347 is associated with increased risk of coronary heart disease and lower plasma apolipoprotein AIV levels. Circ Res. 2003;92(9):969-75.

Cotton JM, Hong Y, Hawe E, Mathur A, Humphries SE, Brown AS, Martin JF, Erusalimsky JD. Rise of circulating thrombopoietin following cardiothoracic surgery is potentiated in patients with coronary atherosclerosis: correlation with a preceding increase in levels of interleukin-6. Thromb Haemost. 2003;89(3):538-43.

Cannuscio CC, Genovese M, DeMuro-Mercon CJ, Cai B, Holmes R, Gottesdiener KM. Markers of cardiovascular risk in patients with rheumatoid arthritis (RA) and osteoarthritis (OA). Poster presented at the 67th Annual Scientific Meeting of the American College of Rheumatology; 2003.

Steenbergen C, Afshari CA, Petranka JG, Collins J, Martin K, Bennett L, Haugen A, Bushel P, Murphy E. Alterations in apoptotic signaling in human idiopathic cardiomyopathic hearts in failure. Am J Physiol Heart Circ Physiol. 2003 Jan 1;284(1):H268-76.

Gomma AH, Elrayess MA, Knight C, Hawe E, Fox KM, Humphries SE. The endothelial nitric oxide synthase (Glu298Asp and -786T>C) gene polymorphisms are associated with coronary in-stent restenosis. Eur Heart J. 2002 Dec;23(24):1955-62.

Anthony MS. Soy protein and coronary heart disease and CHD risk factors. Presented at the 2nd International Symposium on Soybean and Human Health; November 15, 2002. Seoul, South Korea.

Rivero E, Varas-Lorenzo C, Rueda de Castro A, Blanch C, Maguire A. Long-term prediction of coronary heart disease risk in a renal transplant clinical trial. Poster presented at the 18th ICPE International Conference on Pharmacoepidemiology; August 21, 2002. Edinburgh, Scotland. [abstract] Pharmacoepidemiol Drug Saf. 2002 Aug 21; 11(Suppl 1):S152.

Noronha IL, Eisen HJ, Pedersen PR, Rivero E. Long-term predicted probability of coronary heart disease in renal transplant recipients treated with everolimus or MMF: an estimation based on the first year of treatment by applying a Framingham prediction model. Poster presented at the XIX International Congress of the Transplantation Society; August 2002. Miami, FL.

Anthony MS. Phytoestrogens and cardiovascular disease: where's the meat? - Invited editorial. Arterioscler Thromb Vasc Biol. 2002 Aug 1;22(8):1245-7.

Anthony MS. Soy protein versus isoflavones in the prevention of cardiovascular disease. Presented at the Food as Drug Meeting; April 11, 2002. Turku, Finland.

Frost L, Johnsen SP, Pedersen L, Husted S, Engholm G, Sorensen HT, Rothman KJ. Seasonal variation in hospital discharge diagnosis of atrial fibrillation: a population-based study. Epidemiology. 2002 Mar;13(2):211-5.

Flavell DM, Jamshidi Y, Hawe E, Pineda Torra I, Taskinen MR, Frick MH, Nieminen MS, Kesäniemi YA, Pasternack A, Staels B, Miller G, Humphries SE, Talmud PJ, Syvänne M. Peroxisome proliferator-activated receptor alpha gene variants influence progression of coronary atherosclerosis and risk of coronary artery disease. Circulation. 2002 Feb 25;105(12):1440-5.

Djousse L, Rothman KJ, Cupples LA, Levy D, Ellison RC. Serum albumin and risk of myocardial infarction and all-cause mortality in the Framingham Offspring Study. Circulation. 2002 Jan 1;106(23):2919-24.

Talmud PJ, Hawe E, Miller GJ, Humphries SE. Nonfasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men. Arterioscler Thromb Vasc Biol. 2002;22(11):1918-23.

Talmud PJ, Hawe E, Martin S, Olivier M, Miller GJ, Rubin EM, Pennacchio LA, Humphries SE. Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides. Hum Mol Genet. 2002;11(24):3039-46.

Talmud PJ, Hawe E, Robertson K, Miller GJ, Miller NE, Humphries SE. Genetic and environmental determinants of plasma high density lipoprotein cholesterol and apolipoprotein AI concentrations in healthy middle-aged men. Ann Hum Genet. 2002;66(Pt 2):111-24.

Talmud PJ, Hawe E, Miller GJ. Analysis of gene-environment interaction in coronary artery disease: lipoprotein lipase and smoking as examples. J Cardiovasc Med. 2002;3(1):6-9 Revie.

Vitolins MZ, Anthony MS, Burke GL. Epidemiology of soy isoflavones and cardiovascular disease. In: Gilani GS, Anderson JJB, editors. Phytoestrogens and health. Champaign: IL. AOCS Press; 2002. p.260-7.

Juhan-Vague I, Morange PE, Aubert H, Henry M, Aillaud MF, Alessi MC, Samnegard A, Hawe E, Yudkin J, Margaglione M, Di Minno G, Hamsten A, Humphries SE, HIFMECH Study Group. HIFMECH Study Group. Plasma thrombin-activatable fibrinolysis inhibitor antigen concentration and genotype in relation to myocardial infarction in the north and south of Europe. Arterioscler Thromb Vasc Biol. 2002;22(5):867-73.

Adams MR, Golden DL, Anthony MS, Williams JK. Inhibitory effects of soy protein isolate on atherosclerosis in mice do not require the presence of LDL receptors or effects on plasma lipoproteins. J Nutr. 2002;132:602S.

Rivero E, Varas-Lorenzo C, Maguire AR, Eisen HJ, Pedersen TR, Nashan B, Elkammas E. 10-Year predicted probability of coronary heart disease in renal transplant recipients treated with everolimus or mmf. Poster presented at the American Transplant Congress; April 2002. Washington, DC. [abstract] Am J Transplant. 2002; 2(Suppl 3):418.

Jamshidi Y, Flavell DM, Hawe E, MacCallum PK, Meade TW, Humphries SE. Genetic determinants of the response to bezafibrate treatment in the lower extremity arterial disease event reduction (LEADER) trial. Atherosclerosis. 2002;163(1):183-92.

Pladevall-Vila M, Gabriel R, Sanchez LM, Leiva A, Sobrino J, Pelegri A. The com99 study: a cluster-randomized trial of an intervention to improve compliance with medication: preliminary results. Poster presented at the19th Scientific Meeting of the International Society of Hypertension; 2002. Prague, Czech Republic.

Pladevall-Vila M, Gabriel R, Arnau A, Sobrino J, Pelegri A, Felip A. The com99 study: a cluster-randomized trial of an intervention to improve compliance: design and baseline characteristics of patients. Poster presented at the 19th Scientific Meeting of the International Society of Hypertension; 2002; 2002. Prague, Czech Republic.

Bell TJ, Hoerger TJ, Tran MH, Candrilli SD, Wojczynski MK. Distribution of low-density lipoprotein cholesterol levels and treatment patterns in treatment-eligible United States adults based on the ncep atp iii guidelines. Poster presented at the 3rd Scientific Forum on Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke; September 2001.

Buchner DA, Graboys TB, Johnson K, Mordin MM, Goodman L, Partsch DS, Goss TF. Development and validation of the ITG Health-Related Quality-of- Life Short-Form measure for use in patients with coronary artery disease. Integrated Therapeutics Group. Clin Cardiol. 2001 Aug;24(8):556-63.

Lurdes Comas Mongay M, Castellote Alonso E, Feixas Roma J, Pladevall-Vila M. TheCholesterol2000document: is itusefulforrenalpatients? Rev Esp Cardiol. 2001 Jun;54(6):807-8.

Anthony MS. Soy and cardiovascular disease. Presented at the 11th World Congress of Food Science and Technology; April 22, 2001. Seoul, South Korea.

Guyer H, Pladevall-Vila M, Yanez A, Falces C, Sadurni J, Ribes A, Pare C. The relationship between syndrome x and left ventricular hypertrophy: the impact of different methods of adjusting left ventricular mass. Poster presented at the AHA Conference on Cardiovascular Epidemiology; 2001.

Talmud PJ, Berglund L, Hawe E, Waterworth DM, Isasi CR, Deckelbaum RE, Starc T, Ginsberg HN, Humphries SE, Shea S. Age-related effects of genetic variation on lipid levels: the Columbia University BioMarkers Study. Pediatrics. 2001;108(3):E50.

Dekou V, Gudnason V, Hawe E, Miller GJ, Stansbie D, Humphries SE. Gene-environment and gene-gene interaction in the determination of plasma homocysteine levels in healthy middle-aged men. Thromb Haemost. 2001;85(1):67-74.

Feldman HA, Johannes CB, Araujo AB, Mohr BA, Longcope C, McKinlay JB. Low dehydroepiandrosterone and ischemic heart disease in middle-aged men: prospective results from the Massachusetts Male Aging Study. Am J Epidemiol. 2001 Jan 1;153(1):79-89.

Varas-Lorenzo C, Perez-Gutthann S, Castellsague J, Gutierrez LP. Effects of transdermal hormone replacement therapy on cardiovascular outcomes: epidemiological evidence. In: Genazzani AR, editors. Hormone replacement therapy and cardiovascular disease. New York: United States. The Partenon Publishing Group Limited; 2001.

Anthony MS. Soy protein and heart disease. In: Descheemaeker K, Debruyne I, editors. Soy and health 2000 clinical evidence-dietetic applications. Belgium. Garant, Leuven/Apeldoorn; 2001. p.11-6.

Humphries SE, Luong LA, Ogg MS, Hawe E, Miller GJ. The interleukin-6 -174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. Eur Heart J. 2001;22(24):2243-52.

Humphries SE, Talmud PJ, Hawe E, Bolla M, Day IN, Miller GJ. Apolipoprotein E4 and coronary heart disease in middle-aged men who smoke: a prospective study. Lancet. 2001;358(9276):115-9.

Beard SM, Gaffney L, Backhouse ME. An economic evaluation of ramipril in the treatment of patients at high risk for cardiovascular events due to diabetes mellitus. J Med Econ. 2001 Jan 1;4:199-205.

Anthony MS. Soy and cardiovascular disease: cholesterol lowering and beyond. Presented at the European Week of Soy, sponsored by Alpro Soya; October 3, 2000. Ghent, Belgium. Previously presented at the 3rd International Symposium on the Role of Soy in Preventing and Treating Chronic Disease.

Miller K, Santanello NC, Kolman C, Turpin JA, Rhodes T, DeMuro-Mercon CJ. Enalapril pediatric experience study. Poster presented at the 18th Scientific Meeting of the International Society of Hypertension; August 2000.

Anthony MS. Phytoestrogens and the cardiovascular system. Presented at the 5th European Congress on Menopause; July 1, 2000. Copenhagen, Denmark.

Varas-Lorenzo C, Garcia-Rodriguez LA, Perez-Gutthann S, Duque-Oliart A. Hormone replacement therapy and incidence of acute myocardial infarction. A population-based nested case-control study. Circulation. 2000 Jun 6;101(22):2572-8.

Pladevall-Vila M, Guyer H, Yañez A, Sadurni J, Falces C, Planes A, Ribes A. Left ventricular mass is associated with fasting leptin in women but not in men. Poster presented at the International Society of Hypertension; June 2000. [abstract] J Hypertens. 18:S168.

Feldman HA, Johannes CB, Derby CA, Kleinman KP, Mohr BA, Araujo AB, McKinlay JB. Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts Male Aging Study. Prev Med. 2000 Apr 1;30(4):328-38.

Anthony MS. Soy and cardiovascular disease: cholesterol lowering and beyond. J Nutr. 2000 Mar;130(3):662S-3S.

Guyer H, Pladevall-Vila M, Yanez A, Sadurni J, Falces C, Planes A, Ribes A. Assessing the relationship between left ventricular hypertrophy and the insulin resistance syndrome: the influence of different methods of indexing left ventricular mass. Presented at the European Society of Hypertension; 2000.

Yañez A, Gabriel R, Pladevall-Vila M, Suarez C, Guyer H, Aquilar R. The effect of different echocardiographic diagnostic criteria on the prevalence of the left ventricular hypertrophy in Spain. Poster presented at the International Society of Hypertension; 2000.